Achieve Life Sciences Inc logo

Achieve Life Sciences Inc(ACHV)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$6.14
11/17/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ACHV

11/17/2026: ACHV (1-star) is currently NOT-A-BUY. Pass it for now.

Achieve Life Sciences is a late-stage clinical specialty pharmaceutical company focused on developing cytisinicline for smoking and nicotine vaping cessation. Its main business strengths include promising Phase 3 trial data and a robust cash position exceeding $200 million. The primary growth story centers on addressing the multi-billion-dollar nicotine addiction market with a differentiated therapeutic option. Key risks involve pre-revenue financial status, reliance on a single lead product candidate, and regulatory execution. The stock suits high-risk growth investors monitoring upcoming regulatory milestones and commercialization readiness.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveOffers significant capital appreciation potential tied to late-stage clinical trial milestones and commercial drug launch catalysts.
Momentum investorStrong fit while signal remains positiveStock price behavior is frequently sensitive to near-term clinical readouts, regulatory updates, and volume breakouts.
Value investorWeak fitPre-revenue financial profile with recurring operating losses means traditional value metrics do not currently apply.
Dividend investorWeak fitThe company does not pay dividends and retains all cash for clinical development.
Low-risk investorWeak fitHigh clinical, regulatory, and price volatility risks are inherent to pre-commercial biotechnology stocks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology stocks experience sharp price fluctuations based on trial results and regulatory announcements.
Valuation riskHighValuation relies heavily on future commercial projections rather than current trailing revenue or earnings.
Competition risk (generic varenicline and OTC nicotine replacements)Medium / highThe company must effectively compete against well-entrenched generic alternatives and standard over-the-counter options.
Business qualityMediumRepresents a specialized pharmaceutical pipeline asset backed by promising late-stage clinical data.
Dividend incomeLow / noneNo dividend distributions are provided or anticipated in the near term.
Execution riskHighSuccess depends entirely on navigating regulatory approval processes and executing a successful commercial rollout.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 746.03M USD
Price to earnings Ratio -
1Y Target Price 13.75
Price to earnings Ratio -
1Y Target Price 13.75
Volume (30-day avg) 1.2M shares
Beta 2.41
52 Weeks Range 2.62 - 8.64
Updated Date 11/15/2026
52 Weeks Range 2.62 - 8.64
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.41

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.0%
Active BUY / eligible
67 / 108
30-Day BUY Count Change
+22
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
43.6%
Active BUY / eligible
17 / 39
30-Day BUY Count Change
+10

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -42.9%
Avg. Invested days 28
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/17/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ACHV receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
ACHV has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-37.2%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
ACHV's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
ACHV's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-37.2%, negative) and free-cash-flow growth (-66.2%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 88.1% and approximately 79.3% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.85%, which materially reduces the ownership score.

Top 5 Institutional Investors

Frazier Life Sciences Management, L.P. 6.92%
TPG GP A, LLC 6.25%
venBio Partners LLC 5.38%
Logos Global Management LP 4.93%
BlackRock Inc 4.79%

Unit Economics (Per $1K Revenue)

★★★★★
ACHV generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
ACHV has a liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Therapeutic Product Pipeline (Pre-commercial)Future sales, licensing fees, and commercialization royalties for cytisinicline upon regulatory approval.The company currently generates no commercial revenue and is funded by cash reserves and capital markets until drug approval.

Valuation

Trailing PE -
Forward PE 35.34
Enterprise Value 488.14M
Price to Sales(TTM) 5.09
Enterprise Value 488.14M
Price to Sales(TTM) 5.09
Enterprise Value to Revenue 0.63
Enterprise Value to EBITDA -2.42
Shares Outstanding 110.03M
Shares Floating 87.25M
Shares Outstanding 110.03M
Shares Floating 87.25M
Percent Insiders 0.85
Percent Institutions 88.06

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.